- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
53
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
53 companies
Madrigal Pharmaceuticals
Market Cap: US$11.4b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$496.54
7D
-0.09%
1Y
52.2%
Arcutis Biotherapeutics
Market Cap: US$3.2b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$25.45
7D
-4.7%
1Y
85.5%
Marker Therapeutics
Market Cap: US$30.0m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$1.63
7D
-25.6%
1Y
-15.3%
Ardelyx
Market Cap: US$1.9b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$7.86
7D
-1.6%
1Y
43.4%
Capricor Therapeutics
Market Cap: US$1.2b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$21.57
7D
-11.3%
1Y
51.2%
Pelthos Therapeutics
Market Cap: US$79.9m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$24.69
7D
7.2%
1Y
12.2%
Lineage Cell Therapeutics
Market Cap: US$395.0m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.58
7D
-4.8%
1Y
162.2%
ARS Pharmaceuticals
Market Cap: US$1.0b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.06
7D
-3.6%
1Y
-29.7%
Aldeyra Therapeutics
Market Cap: US$333.3m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.42
7D
8.6%
1Y
4.6%
Achieve Life Sciences
Market Cap: US$245.4m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.36
7D
-19.6%
1Y
35.4%
RenovoRx
Market Cap: US$33.0m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.90
7D
-9.7%
1Y
-33.8%
Soleno Therapeutics
Market Cap: US$2.2b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$41.60
7D
-4.9%
1Y
-16.5%
AC Immune
Market Cap: US$350.3m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.47
7D
2.1%
1Y
31.4%
Viridian Therapeutics
Market Cap: US$3.2b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$33.62
7D
4.1%
1Y
73.0%
Syndax Pharmaceuticals
Market Cap: US$1.9b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$20.55
7D
0.1%
1Y
44.3%
Citius Oncology
Market Cap: US$97.1m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$1.09
7D
-5.2%
1Y
-9.2%
Longeveron
Market Cap: US$12.4m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.59
7D
11.5%
1Y
-61.4%
Caris Life Sciences
Market Cap: US$7.3b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$26.50
7D
4.0%
1Y
n/a
Precigen
Market Cap: US$1.7b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.46
7D
0%
1Y
243.1%
Vera Therapeutics
Market Cap: US$3.3b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$45.11
7D
-1.4%
1Y
18.9%
Altimmune
Market Cap: US$674.6m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$5.12
7D
10.8%
1Y
-26.3%
Insmed
Market Cap: US$34.7b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$155.89
7D
-0.3%
1Y
99.9%
Ocugen
Market Cap: US$521.3m
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.
OCGN
US$1.54
7D
3.4%
1Y
108.2%
BioRestorative Therapies
Market Cap: US$9.8m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.14
7D
-0.9%
1Y
-51.5%
Unicycive Therapeutics
Market Cap: US$154.7m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$7.02
7D
6.4%
1Y
32.4%
Rhythm Pharmaceuticals
Market Cap: US$7.0b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$102.67
7D
-3.1%
1Y
79.5%
Praxis Precision Medicines
Market Cap: US$8.7b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$309.92
7D
-0.9%
1Y
318.7%
Roivant Sciences
Market Cap: US$15.7b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
ROIV
US$21.91
7D
-4.7%
1Y
96.9%
Cogent Biosciences
Market Cap: US$5.9b
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$38.36
7D
-3.9%
1Y
312.5%
Fortress Biotech
Market Cap: US$107.4m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.38
7D
-2.3%
1Y
94.3%
Ionis Pharmaceuticals
Market Cap: US$13.3b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$81.92
7D
3.1%
1Y
149.1%
Prelude Therapeutics
Market Cap: US$174.7m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.97
7D
8.2%
1Y
72.1%
Day One Biopharmaceuticals
Market Cap: US$1.3b
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$11.78
7D
-2.4%
1Y
-9.5%
Savara
Market Cap: US$1.4b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$5.61
7D
-9.4%
1Y
110.1%
Creative Medical Technology Holdings
Market Cap: US$7.5m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$2.09
7D
7.2%
1Y
-34.9%
Amicus Therapeutics
Market Cap: US$4.4b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.28
7D
-0.5%
1Y
48.9%